Centauri Therapeutics

The company's core technology is the proprietary Alphamer® platform, which is based on the concept of "programmable immunity". This approach utilizes chemically synthesized molecules designed to redirect the body's pre-existing antibodies to target pathogens, engaging both the innate and adaptive immune systems to clear infections. The Alphamer molecules are modular, consisting of a targeting component that binds to the pathogen and an effector part that recruits the patient's own antibodies. This dual-mechanism approach has shown potential to be effective even in immune-compromised patients and to combat antimicrobial resistance (AMR).

Centauri's business model is centered on the research and development of its pipeline candidates, funded through a combination of private investment, grants, and venture capital. The company has received significant funding from organizations like CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to advance its lead program, ABX-01, a broad-spectrum antimicrobial aimed at treating drug-resistant Gram-negative bacteria. Key investors include Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund. The company's primary focus is on advancing its therapeutic candidates through preclinical and eventually into first-in-human clinical trials.